Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityNovel compounds for the treatment of HIV type-1 infection.Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
P2860
Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics of BILR 355 a ...... d with a low dose of ritonavir
@en
Pharmacokinetics of BILR 355 a ...... with a low dose of ritonavir.
@nl
type
label
Pharmacokinetics of BILR 355 a ...... d with a low dose of ritonavir
@en
Pharmacokinetics of BILR 355 a ...... with a low dose of ritonavir.
@nl
prefLabel
Pharmacokinetics of BILR 355 a ...... d with a low dose of ritonavir
@en
Pharmacokinetics of BILR 355 a ...... with a low dose of ritonavir.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of BILR 355 a ...... d with a low dose of ritonavir
@en
P2093
Charles Ballow
Fenglei Huang
Joseph Scherer
Kristin Drda
Lois Rowland
Mark Castles
Patrick Robinson
Thomas R MacGregor
Thuy Nguyen
P2860
P304
P356
10.1128/AAC.00752-08
P407
P577
2008-10-27T00:00:00Z